drugset / Trial / NCT05980091

Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.

NCT05980091

Phase 1 Suspended 316 enrolled ART Fertility Clinics LLC
RandomizedParallel-groupOpen-labelBasic science

Summary

The goal of this study is to compare the difference in clinical pregnancy, miscarriage and livebirth rate between day 6 euploid blastocyst transfer on the 6th and the 7th day of progesterone exposure in Hormonal Replacement Therapy (HRT) FET cycles. This prospective \& randomized study will only include euploid day 6 blastocysts. This will be the first prospective study of euploid day 6 blastocysts thereby excluding aneuploidy as a cause of miscarriage and implantation failure. The point of randomization will occur on the day of progesterone commencement.

Timeline

Start
2023-09-22
Primary completion
2026-12-30
Completion
2026-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 100 mg Other
Background estradiol valerate Unknown 6 mg

Indications